



Cytokinetics to Present Clinical Trial Data Relating to CK-2017357 in Patients With Amyotrophic Lateral Sclerosis

November 22, 2011 9:01 PM EST

Results to Be Presented at the 22nd International Symposium on ALS/MND

SOUTH SAN FRANCISCO, CA, Nov 22, 2011 (MARKETWIRE via COMTEX) --

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two posters are scheduled to be presented at the 22nd International Symposium on ALS/MND to be held November 30, 2011 - December 2, 2011 at the Hilton Sydney in Sydney, Australia.

One poster will present data from the first cohort, or Part A, of an ongoing Phase II clinical trial evaluating multiple fixed doses of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS) who are not receiving riluzole. The other poster will review the history of the ALS Functional Rating Scale - Revised (ALSFRRS-R). CK-2017357 selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, which increases skeletal muscle force in response to neuronal input and delays the onset and reduces the degree of muscle fatigue. CK-2017357 is the lead drug candidate that has emerged from the company's skeletal muscle contractility program.

Poster Presentations at the 22nd International Symposium on ALS/MND

Date: Thursday, December 1, 2011 Presentation Time: 11:50 AM - 12:30 PM Australian Eastern Daylight Time (on display beginning Wednesday, November 30) Poster #: SW216 Session: 12A - Resources & Repositories; Scientific Work in Progress Title: A Study to Evaluate Safety, Tolerability and Clinical Outcomes Following Repeated Doses of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis

Presenter: Jeffrey M. Shefner, M.D., Ph.D., Professor and Chair, Department of Neurology at the Upstate Medical University, State University of New York

Date: Wednesday, November 30, 2011 Presentation Time: 6:45 PM - 7:15 PM Australian Eastern Daylight Time (on display beginning Wednesday, November 30) Poster #: P92 Session: 6 - Therapeutic Strategies

Title: The ALSFRS @ 20: Evolution of the ALSFRS-R, History, Clinimetric Properties and Future Directions Presenter: Jesse Cedarbaum, MD, Vice President of Clinical Research and Operations, Neuroscience and Neuromuscular Disorders

About the International Symposium on ALS/MND

The International Symposium on ALS/MND is a unique annual event that brings together leading international researchers and health and social care professionals to present and debate key innovations in their respective fields. The International Symposium is the premier forum for both biomedical research and clinical investigation and practice for those interested in improving care, understanding disease pathogenesis and developing novel treatments for ALS/MND. For more information, visit <http://www.alsmndalliance.org/>.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase II clinical trials program and has been granted orphan-drug designation by the U.S. Food and Drug Administration for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment in which CK-2017357 demonstrated potentially clinically relevant pharmacodynamic effects in a Phase IIa trial. Cytokinetics is also conducting research directed to compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions associated with excessive smooth muscle contraction, such as bronchoconstriction associated with asthma and chronic obstructive pulmonary disorder (COPD). In addition, prior Cytokinetics' research generated three anti-cancer drug candidates that have progressed into clinical development: ispinesib, SB-743921 and GSK-923295. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact: [

Christopher S. Keenan
(Investors and Media)

Director, Investor Relations
(650) 624-3000

SOURCE: Cytokinetics, Inc.